Study comfort and medication use after CAR-T therapy
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at quality of life and how medicines are used for people who are getting CAR-T cell therapy for DLBCL. It aims to better understand what helps patients feel and function during follow-up after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Be scheduled to receive CAR-T cell therapy for DLBCL (not in another CAR-T trial)
- Have follow-up care through the Hematology department at Hospices Civils de Lyon
- Have no major mental health condition that could make study visits or questions difficult (as judged by the study doctor)
- You must agree not to object and allow participation in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a biological process called trogocytosis (when immune cells swap pieces of their outer coating) to see if it can help predict how well CAR-T cell therapy works for people with a type of lymphoma called diffuse large B-cell lymphoma.
This study looks at factors that predict how well CAR-T therapy works for large B-cell lymphoma that has come back or not responded to treatment. It aims to help doctors better identify who may benefit from this therapy.
This study looks at how thinking and brain function change over time in people with lymphoma who receive CAR T therapy. It may help doctors understand side effects and better support patients during and after treatment.
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
This study is looking at why some people develop low blood cell counts after CAR-T therapy for a type of lymphoma. It aims to find ways to help the bone marrow recover and work better.
Hear when a new Patients With Diffuse Large B-cell Lymphoma Treated With CART-cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.